DocMeetings

Following Huggins development of the first systemic treatment for metastatic cancer androgen deprivation has been central to the management of mHSPC. However, recently we have realised it is not so simple. Exactly what is metastatic disease and how do new imaging modalities challenge our understanding? What is the role for local treatment? What about oligometastatic disease, does it exist and should we treat it differently? It is also clear that combination therapy is associated with clinically significant improvements in survival. However, what should we use in whom and if it is so good why do so few men get it?

Just some of the questions we will answer as we try and separate the facts and the belief.